Second-line drug susceptibilities of multidrug-resistant tuberculosis strains isolated in Thailand: An update

International Journal of Tuberculosis and Lung Disease

Volumn 18, Issue 8, 2014, Pages 961-963

  Chaiprasert, A ^a,b   Srimuang, S ^b   Tingtoy, N ^a   Makhao, N ^b   Sirirudeeporn, P ^b   Tomnongdee, N ^b   Theankeaw, O ^b   Charoensook, S ^b   Leechawengwongs, M ^b,c   Prammananan, T ^b,d  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c Vichaiyut Hospital   (Thailand)

^d NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT AGENCY   (Thailand)

Author keywords

Anti tuberculosis drug; Resistance; Tuberculosis

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMINOSALICYLIC ACID; ETHIONAMIDE; GATIFLOXACIN; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; QUINOLONE DERIVATIVE; ACETAMIDE DERIVATIVE; OXAZOLIDINONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; SPUTUM ANALYSIS; THAILAND; DRUG EFFECTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ACETAMIDES; AMINOGLYCOSIDES; ANTITUBERCULAR AGENTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OXAZOLIDINONES; THAILAND; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84904563231     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.13.0197     Document Type: Article

References (8)

1. Zignol M, van Gemert W, Falzon D, et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ 2012; 90: 111-119D.
2. World Health Organization. Global tuberculosis control. WHO report 2011. WHO/HTM/TB/2011.16. Geneva, Switzerland: WHO, 2011.
3. Kent P T, Kubica G P. Public health microbiology, a guide for the level III laboratory. Atlanta, GA, USA: Department of Health and Human Services, Centers for Disease Control and Prevention, 1985.
4. Prammananan T, ArjratanakoolW, Chaiprasert A, et al. Second-line drug susceptibilities of Thai multidrug-resistant Mycobacterium tuberculosis isolates. Int J Tuberc Lung Dis 2005; 9: 216-219. (Pubitemid 40278387)
5. Prammananan T, Chaiprasert A, Leechawengwongs M. 8-years experience of fluoroquinolone susceptibility testing of multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand. Int J Antimicrob Agents 2011; 37: 84-85.
6. Huang T S, Kunin C M, Shin-Jung Lee S, Chen Y S, Tu H Z, Liu Y C. Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003. J Antimicrob Chemother 2005; 56: 1508-1562.
7. Said H M, Kock M M, Ismail N A, et al. Molecular characterization and second-line antituberculosis drug resistance patterns of multidrug-resistant Mycobacterium tuberculosis isolates from the northern region of South Africa. J Clin Microbiol 2012; 50: 2857-2862.
8. Sherma S K, George N, Kadhiravan T, Saha P K, Mishra H K, Hanif M. Prevalence of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: a retrospective hospital-based study. Indian JMed Res 2009; 130: 392-395.